The announcement of positive study results often leads to increased investor confidence, as it suggests potential for new product development and future revenue streams. In this case, the results could lead to further investigation of THIO conjugates as second-generation cancer therapies, potentially expanding MAIA's product pipeline and positively impacting its stock in the short term.